Morphotek, Inc., a subsidiary of Eisai Inc., has launched its Antibody Drug Conjugate (ADC) Services business based on its REsidue-SPEcific Conjugation Technology (RESPECT) and eribulin-linker toxin platforms. RESPECT is a site-specific conjugation technology that targets select amino acid residues as a way of producing investigational homogeneous ADCs with defined drug-to-antibody ratios. The platform allows for site-specific conjugation of a single cytotoxic payload or two payloads with differ...